CN1333830A - 用于治疗和诊断卵巢癌的组合物和方法 - Google Patents

用于治疗和诊断卵巢癌的组合物和方法 Download PDF

Info

Publication number
CN1333830A
CN1333830A CN99815694A CN99815694A CN1333830A CN 1333830 A CN1333830 A CN 1333830A CN 99815694 A CN99815694 A CN 99815694A CN 99815694 A CN99815694 A CN 99815694A CN 1333830 A CN1333830 A CN 1333830A
Authority
CN
China
Prior art keywords
polynucleotide
ovarian cancer
sequence
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99815694A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·米特查姆
G·E·金
P·A·阿尔盖特
T·N·弗鲁达奇斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27499016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1333830(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/216,003 external-priority patent/US6670463B1/en
Priority claimed from US09/215,681 external-priority patent/US6528253B1/en
Priority claimed from US09/338,933 external-priority patent/US6488931B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CN1333830A publication Critical patent/CN1333830A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN99815694A 1998-12-17 1999-12-17 用于治疗和诊断卵巢癌的组合物和方法 Pending CN1333830A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/216,003 US6670463B1 (en) 1998-12-17 1998-12-17 Compositions and methods for therapy of ovarian cancer
US09/215,681 US6528253B1 (en) 1998-12-17 1998-12-17 Compositions and methods for diagnosis of ovarian cancer
US09/215,681 1998-12-17
US09/216,003 1998-12-17
US09/338,933 US6488931B1 (en) 1998-12-17 1999-06-23 Compositions and methods for therapy and diagnosis of ovarian cancer
US09/338,933 1999-06-23
US09/404,879 US6468546B1 (en) 1998-12-17 1999-09-24 Compositions and methods for therapy and diagnosis of ovarian cancer
US09/404,879 1999-09-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200810183705A Division CN101816788A (zh) 1998-12-17 1999-12-17 用于治疗和诊断卵巢癌的组合物和方法

Publications (1)

Publication Number Publication Date
CN1333830A true CN1333830A (zh) 2002-01-30

Family

ID=27499016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99815694A Pending CN1333830A (zh) 1998-12-17 1999-12-17 用于治疗和诊断卵巢癌的组合物和方法

Country Status (15)

Country Link
US (2) US6468546B1 (enExample)
EP (1) EP1141290B1 (enExample)
JP (1) JP2002532093A (enExample)
CN (1) CN1333830A (enExample)
AU (1) AU2197800A (enExample)
BR (1) BR9916207A (enExample)
CA (1) CA2354156A1 (enExample)
HU (1) HUP0104717A3 (enExample)
IL (1) IL143633A0 (enExample)
MX (1) MXPA01006110A (enExample)
NO (1) NO20013002L (enExample)
NZ (1) NZ512247A (enExample)
PL (1) PL201529B1 (enExample)
TR (2) TR200200937T2 (enExample)
WO (1) WO2000036107A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619833A (zh) * 2012-09-11 2015-05-13 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
CN107531782A (zh) * 2015-03-27 2018-01-02 南加利福尼亚大学 用于表达b7‑h4的实体肿瘤的治疗的car t‑细胞

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP3764286B2 (ja) * 1998-11-12 2006-04-05 独立行政法人科学技術振興機構 タンパク質ＡＭＳＨとそのｃＤＮＡ
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6670463B1 (en) 1998-12-17 2003-12-30 Corixa Corporation Compositions and methods for therapy of ovarian cancer
CZ303339B6 (cs) * 1998-12-17 2012-08-08 Corixa Corporation Izolovaná protilátka nebo její fragment vázající antigen, jejich použití a farmaceutický prostredek pro lécení ovariálního karcinomu
US6699664B1 (en) 1998-12-17 2004-03-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) * 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20020146727A1 (en) * 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US20020051990A1 (en) * 2000-06-09 2002-05-02 Eric Ople Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
EP1301524A1 (en) * 2000-06-30 2003-04-16 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
AU2001273194A1 (en) * 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
JP4942906B2 (ja) * 2000-07-17 2012-05-30 コリクサ コーポレイション 卵巣癌の治療および診断のための組成物および方法
US20110177082A1 (en) * 2000-07-17 2011-07-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002010187A1 (en) * 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
CA2422215A1 (en) 2000-09-20 2002-03-28 Amgen Inc. B7-like molecules and uses thereof
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
AU2002254615A1 (en) * 2001-04-17 2002-10-28 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US20030039999A1 (en) 2001-05-25 2003-02-27 Amgen, Inc. B7 related protein-2 molecules and uses thereof
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
US20030190621A1 (en) * 2002-03-20 2003-10-09 Ken-Shwo Dai Human CrkRS-related gene variant associated with lung cancers
US8076080B2 (en) * 2002-05-21 2011-12-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
UA89348C2 (ru) * 2002-10-16 2010-01-25 Евро-Селтик С.А. Изолированное моноклональное антитело, которое связывает клеточно-ассоциированный полипептид са 125/о772р
DK1551876T3 (da) * 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
AU2003294355A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
WO2004053079A2 (en) * 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US7635560B2 (en) * 2003-04-17 2009-12-22 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US20050163772A1 (en) * 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7192709B2 (en) * 2004-03-15 2007-03-20 Digigenomics Co., Ltd. Methods for identification, assessment, prevention, and therapy of cancer
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
EP1868647A4 (en) * 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
JP3943118B2 (ja) * 2005-04-28 2007-07-11 Ｓｂシステム株式会社 電子情報保存方法及び装置、電子情報分割保存方法及び装置、電子情報分割復元処理方法及び装置並びにそれらのプログラム
US8609816B2 (en) * 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
US20070264407A1 (en) * 2006-05-15 2007-11-15 Pepsico, Inc. Stabilizer for dairy products
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
EP2586458B1 (en) * 2006-12-27 2016-08-24 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
TW202144388A (zh) * 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
JP2001523472A (ja) 1997-11-18 2001-11-27 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
JP2004516802A (ja) * 1998-06-02 2004-06-10 ジェネンテック・インコーポレーテッド 膜結合タンパク質及びそれをコードする核酸
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE413466T1 (de) 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1159619A2 (en) 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Methods of diagnosing and treating breast cancer
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
AU5177100A (en) 1999-06-11 2001-01-02 Human Genome Sciences, Inc. 47 human secreted proteins
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001018542A2 (en) 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1290217A2 (en) 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20020051990A1 (en) 2000-06-09 2002-05-02 Eric Ople Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
EP1301524A1 (en) 2000-06-30 2003-04-16 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
AU2001273194A1 (en) 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1445318A2 (en) 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2002016581A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619833A (zh) * 2012-09-11 2015-05-13 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
CN104619833B (zh) * 2012-09-11 2018-01-02 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
US10092634B2 (en) 2012-09-11 2018-10-09 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
US11266729B2 (en) 2012-09-11 2022-03-08 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
CN107531782A (zh) * 2015-03-27 2018-01-02 南加利福尼亚大学 用于表达b7‑h4的实体肿瘤的治疗的car t‑细胞

Also Published As

Publication number Publication date
BR9916207A (pt) 2001-12-04
NO20013002D0 (no) 2001-06-15
PL349322A1 (en) 2002-07-15
WO2000036107A2 (en) 2000-06-22
HUP0104717A3 (en) 2005-06-28
HUP0104717A2 (hu) 2002-04-29
EP1141290B1 (en) 2010-07-28
NO20013002L (no) 2001-08-15
AU2197800A (en) 2000-07-03
MXPA01006110A (es) 2002-05-06
US6468546B1 (en) 2002-10-22
TR200200937T2 (tr) 2002-06-21
WO2000036107A3 (en) 2001-02-22
US7202334B1 (en) 2007-04-10
IL143633A0 (en) 2002-04-21
EP1141290A2 (en) 2001-10-10
TR200102507T2 (tr) 2002-01-21
JP2002532093A (ja) 2002-10-02
CA2354156A1 (en) 2000-06-22
PL201529B1 (pl) 2009-04-30
NZ512247A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
EP1141290B1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
EP1349870B1 (en) Compositions for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1183348B1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
EP1870466A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2001276973A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002013847A2 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
JP2002543769A (ja) 肺癌の治療および診断のための化合物および方法
WO2001025272A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP1214595A2 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
US20020150588A1 (en) SPAS-1 cancer antigen
JP2002540789A5 (enExample)
US20020022591A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
NZ567750A (en) Compositions and uses for cancer therapy
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
US20030125245A1 (en) Compositions and methods for therapy and diagnosis of lung cancer
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
AU2007216683B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
HK1044021A1 (zh) 用於治療和診斷卵巢癌的組合物和方法
AU2003271300B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
US20030157119A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001027276A2 (en) Dna sequences from breast tumor and uses thereof
CA2613125A1 (en) Compositions and methods for therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044021

Country of ref document: HK